CurrentCardio
Get Weekly

Cardiovascular journalCurrentCardio coverage

JACC: Cardiovascular Interventions

What CurrentCardio has captured from this journal. The coverage figures describe CurrentCardio's coverage, not the journal's output. Figures as of 13 October 2026.

Recent
25 Briefs
past 90 days
Archive
426 Briefs
research published Apr 2023 – Dec 2026
Editorial
–
no Weekly issue published yet
Impact Factor
12.7
2025 · Journal Citation Reports

Topics

Evidence types

Shares are of the 426 Briefs CurrentCardio has covered from JACC Cardiovasc Interv, by primary topic and study type; a Brief without a primary topic is in no topic row.

Publication activity

Latest from JACC: Cardiovascular Interventions

All coverage, newest first

  1. JACC Cardiovasc Interv

    Mechanical Thrombectomy Versus Anticoagulation Alone in Intermediate-High Risk PE

    Randomised controlled trialPulmonary vascular & VTE

  2. JACC Cardiovasc Interv

    Clinical Performance and Reproducibility of the LIRA Method for TAVR in Bicuspid Anatomy

    Cohort studyValvular & structural

  3. JACC Cardiovasc Interv

    Residual Mitral Regurgitation as a Long-Term Predictor of Mortality After Mitral TEER

    Cohort studyValvular & structural

  4. JACC Cardiovasc Interv

    Stenting Technique and Clinical Outcome in True Bifurcation PCI

    Secondary analysisCoronary & ACS

  5. JACC Cardiovasc Interv

    Transcatheter Patent Ductus Arteriosus Closure in Extremely Premature Infants

    Cohort studyCongenital

  6. JACC Cardiovasc Interv

    Impact of Diabetes on Outcomes of Contemporary PCI Guided by OCT vs Angiography

    Secondary analysisCoronary & ACS

  7. JACC Cardiovasc Interv

    Long-Term Outcomes of Contemporary Balloon-Expandable TAVR in Bicuspid Aortic Valve

    Cohort studyValvular & structural

  8. JACC Cardiovasc Interv

    Surgical Bailout During TAVR

    Cohort studyValvular & structural

  9. JACC Cardiovasc Interv

    Ultrashort vs Standard-Duration Dual Antiplatelet Therapy in Acute Coronary Syndrome Patients Undergoing PCI

    Meta-analysisCoronary & ACS

  10. JACC Cardiovasc Interv

    Five-Year Follow-Up of Transcatheter Aortic Valve Replacement With Self-Expanding Intra-Annular Versus Commercially Available Valves

    Randomised controlled trialValvular & structural

  11. JACC Cardiovasc Interv

    1-Year Outcomes of Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent for Coronary Artery Bypass Graft Lesions

    Cohort studyCoronary & ACS

  12. JACC Cardiovasc Interv

    2-Year Patient-Centered and Clinical Outcomes of Sirolimus- Versus Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Artery Disease

    Secondary analysisAortic & peripheral

  13. JACC Cardiovasc Interv

    Impact of Myocardial Bridges on Long-Term Outcomes After Left Anterior Descending Chronic Total Occlusion Recanalization

    Cohort studyCoronary & ACS

  14. JACC Cardiovasc Interv

    Outcomes of Supra-Annular vs Intra-Annular Self-Expanding Valves in Valve-In-Valve Transcatheter Aortic Valve Replacement

    Cohort studyValvular & structural

  15. JACC Cardiovasc Interv

    Rapid Inflation-Deflation vs Pressure-Optimized Stenting During Primary PCI

    Randomised controlled trialCoronary & ACS

  16. JACC Cardiovasc Interv

    Redo–Transcatheter Aortic Valve Replacement With Self-Expanding Valves

    Cohort studyValvular & structural

  17. JACC Cardiovasc Interv

    Impact for Treatment Decision-Making and Clinical Outcome of Angiography-Derived Fractional Flow Reserve

    Randomised controlled trialCoronary & ACS

  18. JACC Cardiovasc Interv

    Prognostic Impact of Definite and Marginal Discordance Between Fractional Flow Reserve and Nonhyperemic Pressure Ratio

    Cohort studyCoronary & ACS

  19. JACC Cardiovasc Interv

    VExUS Score and Hepatorenal Congestion Improvements After Transcatheter Tricuspid Intervention

    Cohort studyValvular & structural

  20. JACC Cardiovasc Interv

    A Multidomain Lifestyle Intervention for Invasively Confirmed ANOCA

    Randomised controlled trialCoronary & ACS

  21. JACC Cardiovasc Interv

    Impact of Aortic Annulus Size on Outcomes After Aortic Valve Replacement

    Secondary analysisValvular & structural

  22. JACC Cardiovasc Interv

    SGLT2 Inhibitor on Infarct Size and LV Remodeling by CMR in Patients With AMI

    Randomised controlled trialCoronary & ACS

  23. JACC Cardiovasc Interv

    Timing of Bleeding and Ischemic Events in High–Bleeding Risk Patients Treated With 1-Month DAPT

    Cohort studyCoronary & ACS

  24. JACC Cardiovasc Interv

    Trends and Outcomes of Antithrombotic Strategies for Valve-in-Valve TAVR

    Cohort studyValvular & structural

  25. JACC Cardiovasc Interv

    Clopidogrel vs Aspirin According to Diabetes Mellitus

    Secondary analysisCoronary & ACS

  26. JACC Cardiovasc Interv

    SCAI/ASE/HRS/SIR/SVS Expert Consensus Statement on Enhanced Radiation Protection

    Guideline or statementCardio-oncology & other

  27. JACC Cardiovasc Interv

    Abbreviated DAPT Regimens Across the Entire Spectrum of Bleeding Risk According to the PRECISE-HBR Score

    Meta-analysisCoronary & ACS

  28. JACC Cardiovasc Interv

    Comparative Efficacy of Endovascular Revascularization Modalities for Symptomatic Infrapopliteal Peripheral Artery Disease

    Meta-analysisAortic & peripheral

  29. JACC Cardiovasc Interv

    Fractional Flow Reserve–Guided Renal Artery Stenting in Renovascular Hypertension

    Randomised controlled trialHypertension

  30. JACC Cardiovasc Interv

    Hospital Volume and Failure to Rescue Post-TAVR

    Cohort studyValvular & structural

  31. JACC Cardiovasc Interv

    Procedural Strategies for Optimal Transcatheter Aortic Valve Replacement

    Research articleValvular & structural

  32. JACC Cardiovasc Interv

    Real-World Outcomes of Dedicated Leaflet Modification for Bioprosthetic Valve-In-Valve TAVR

    Cohort studyValvular & structural

  33. JACC Cardiovasc Interv

    Redo-TAVR (TAV-in-TAV) Best Practices Part 1: Short-in-Short and Short-in-Tall

    Guideline or statementValvular & structural

  34. JACC Cardiovasc Interv

    Redo-TAVR (TAV-in-TAV) Best Practices Part 2: Tall-in-Short and Tall-in-Tall

    Guideline or statementValvular & structural

  35. JACC Cardiovasc Interv

    Leaflet Modification to Mitigate Coronary Obstruction Risk During TAVR

    Cohort studyValvular & structural

  36. JACC Cardiovasc Interv

    Mitral Valve Leaflet Modification

    Research articleValvular & structural

  37. JACC Cardiovasc Interv

    UNICORN During Transcatheter Aortic Valve Replacement in Native and Bioprosthetic Aortic Valves

    Cohort studyValvular & structural

  38. JACC Cardiovasc Interv

    Impact of Leaflet Modification on the Occurrence of Hypoattenuated Leaflet Thickening After Valve-in-Valve Transcatheter Aortic Valve Replacement

    Cohort studyValvular & structural

  39. JACC Cardiovasc Interv

    Leaflet Splitting to Prevent TAVR-Induced Coronary Obstruction in Stented vs Stentless Surgical Bioprosthetic Valves

    Cohort studyValvular & structural

  40. JACC Cardiovasc Interv

    Characteristics of Coronary Intra- or Extramedial Hematomas Causing Emergent Return to Catheterization Laboratory After Percutaneous Coronary Intervention

    Cohort studyCoronary & ACS

All 426 Briefs in ExploreShowing the 40 most recently published